- CNTA +0.91% TFC -0.90%
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the promising stocks to buy under $50. On January 8, Truist analyst Danielle Brill raised the firm’s price target on Centessa to $33 from $30, while keeping a Buy rating on the shares. This decision was made as Truist updated its model, but noted that the company’s fundamental investment thesis remains consistent with its 2025 view.
Needham also increased its price target for Centessa to $38 from $35 with a Buy rating on the shares on January 5. The firm anticipated that the company’s momentum would persist into 2026, driven by upcoming data from Phase 2a dose-escalation cohorts for ORX-750. Furthermore, Needham identified Centessa as one of the most compelling acquisition targets in the biotech sector for the coming year.
Truist Hikes Centessa (CNTA) PT to $33 While Maintaining Consistent 2026 Thesis Earlier on December 10, Oppenheimer resumed coverage of Centessa with an Outperform rating and an increased price target of $62, up from $40. Labeling the company a top pick, the firm highlighted Centessa’s best-in-class orexin agonists and a projected commercial launch in H1 2028. Oppenheimer viewed Centessa as significantly undervalued and anticipated substantial growth driven by clinical data readouts scheduled for 2026 and beyond.
Centessa Pharmaceuticals (NASDAQ:CNTA) is a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.
While we acknowledge the potential of CNTA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Terms and Privacy Policy Privacy Dashboard More Info